Shares of clinical-stage biopharmaceutical company CureVac N.V. (CVAC) are down 10 percent in Wednesday's after-market trading as the company said that its COVID-19 vaccine, CVnCoV, displayed an overall vaccine efficacy of 48 percent against coronavirus of any severity, including single non-respiratory mild symptoms.
The findings were part of results from the company's final analysis of its 40,000 subject international pivotal Phase 2b/3 study or the HERALD study of the first-generation COVID-19 vaccine candidate.
According to the company, its Covid-19 vaccine was shown to have offered protection among participants in the 18-60 age group, with an efficacy of 53 percent against disease of any severity and across all 15 identified strains.
Against the moderate to severe disease, protection was found to be around 77 percent. In the same age group, CVnCoV provided complete protection against hospitalization or death.
In people above 60 years, who were 9 percent of the analyzed cases, the available data did not offer a statistically significant determination of efficacy. The company said that the study will complete the follow-up analyses for trial participants and all important information has been made available to the European Medicines Agency or EMA.
For comments and feedback contact: editorial@rttnews.com
